Determinants of sequence-specific DNA-binding by p48v-myb.

Oncogene

Department of Microbiology, School of Medicine, State University of New York, Stony Brook 11794-8621.

Published: February 1991

The v-myb oncogene of the avian myeloblastosis virus encodes a nuclear protein, p48v-myb, which binds to DNA in a sequence-specific manner. We have used wild type and mutant forms of this protein expressed in E. coli to study the protein and DNA determinants for sequence-specific DNA-binding. We have shown that only the highly conserved domain at the amino terminus of p48v-myb is required for sequence-specific DNA-binding. However, neither of the tandem 50 amino acid repeats present in this domain is alone sufficient for such binding. We have also demonstrated that p48v-myb can recognize a single consensus myb binding site and appears to interact with DNA as a protein monomer. In addition, we have shown that sequence-specific binding by p48v-myb requires nucleotides which flank the previously reported PyAACT/GG consensus.

Download full-text PDF

Source

Publication Analysis

Top Keywords

sequence-specific dna-binding
12
determinants sequence-specific
8
p48v-myb
5
dna-binding p48v-myb
4
p48v-myb v-myb
4
v-myb oncogene
4
oncogene avian
4
avian myeloblastosis
4
myeloblastosis virus
4
virus encodes
4

Similar Publications

Noncoding satellite DNA repeats are abundant at the pericentromeric heterochromatin of eukaryotic chromosomes. During interphase, sequence-specific DNA-binding proteins cluster these repeats from multiple chromosomes into nuclear foci known as chromocenters. Despite the pivotal role of chromocenters in cellular processes like genome encapsulation and gene repression, the associated proteins remain incompletely characterized.

View Article and Find Full Text PDF

Epstein-Barr nuclear antigen 1 (EBNA1), a sequence-specific DNA binding protein of Epstein-Barr virus (EBV), is essential for viral genome replication and maintenance and is therefore an attractive target for the therapeutic intervention of EBV-associated cancers. Several EBNA1-specific inhibitors have demonstrated the ability to block EBNA1 function in vitro, but practical delivery strategies for these inhibitors in vivo are still lacking. Here, we report an intelligent hierarchical targeting theranostic nanosystem (denoted as mZGOCS@MnO-P5) that integrates an azide (N3) terminal dual-targeting peptide (N3-P5), a tumor microenvironment-responsive degradable MnO nanosheet, and a mesoporous ZnGaO:Cr, Sn near-infrared persistent luminescence (NIR-PL) nanosphere (mZGOCS).

View Article and Find Full Text PDF

Investigation of the impact of R273H and R273C mutations on the DNA binding domain of P53 protein through molecular dynamic simulation.

J Biomol Struct Dyn

February 2025

Laboratory of Integrative Genomics, Department of Integrative Biology, School of Bio Sciences and Technology, Vellore Institute of Technology (VIT), Vellore, India.

The P53 protein, a cancer-associated transcriptional factor and tumor suppressor, houses a Zn ion in its DNA-binding domain (DBD), essential for sequence-specific DNA binding. However, common mutations at position 273, specifically from Arginine to Histidine and Cysteine, lead to a loss of function as a tumor suppressor, also called DNA contact mutations. The mutant (MT) P53 structure cannot stabilize DNA due to inadequate interaction.

View Article and Find Full Text PDF

Nuclear receptor subfamily 4 group A member 3 (NR4A3) is a member of the orphan nuclear receptor superfamily, and exhibits transcription factor activity by binding to sequence-specific DNA. Considering that the specific mechanism by which NR4A3 regulates gene transcription in HCC (hepatocellular carcinoma) has not yet been elucidated, our study aimed to explore the transcriptional role of NR4A3 in regulating the target gene CDKN2AIP (CDKN2A interacting protein), which will suppress the development of HCC. Our data show that NR4A3 is downregulated in human HCC tissues, and that low expression of NR4A3 is correlated with poor prognosis, indicating that NR4A3 could act as a tumor suppressor gene in HCC.

View Article and Find Full Text PDF
Article Synopsis
  • Whole genome bisulfite sequencing (WGBS) has been the main method for analyzing DNA methylation but has issues with technical biases that can lead to inaccurate results, especially in cytosine-rich areas.
  • A new technique called EM-seq is emerging to replace WGBS, using a two-step enzymatic conversion process that avoids the damaging effects of bisulfite conversion.
  • EM-seq offers advantages like being degradation-free, requiring less DNA, achieving higher yields, ensuring less variation, and providing accurate and uniform results across a wider range of methylation sites.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!